A Phase 1/2 interventional study of Isatuximab SAR650984 and Cemiplimab REGN2810 in Prostate Cancer and Non-small Cell Lung Cancer, sponsored by Sanofi. Terminated at 16 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-16.
Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Prostatic Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Sanofi.
Among the 34 studies in Prostatic Neoplasms by Sanofi, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 1/2, and was the 34th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 34 studies in Prostatic Neoplasms by Sanofi is open now. The open studies under Prostatic Neoplasms, anywhere →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 16 · Phase 3 10 · Phase 4 5
First in 2001; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 31 interventional studies, 131 across the 2 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 34 studies in Prostatic Neoplasms by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objectives:
Secondary Objectives:
The total study duration per participant was up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Isatuximab dose 1 and REGN2810 predefined dose
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Participants with mCRPC will be given isatuximab dose 2
Drug: Isatuximab SAR650984
Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Isatuximab dose 3 will be given in combination with REGN2810 predefined dose
Drug: Isatuximab SAR650984 · Drug: Cemiplimab REGN2810
Pharmaceutical form: solution for infusion Route of administration: intravenous
Also known as: Sarclisa
Pharmaceutical form: solution for infusion Route of administration: intravenous
Number of Participants With Dose Limiting Toxicities (DLTs)
DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.
Time frame: Cycle 1 (21 days)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.
Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Number of Participants With Laboratory Abnormalities: Hematological Parameters
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Number of Participants With Laboratory Abnormalities: Electrolytes
Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Number of Participants With Laboratory Abnormalities: Renal Parameters
Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.
Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Number of Participants With Laboratory Abnormalities: Liver Function Parameters
Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
Time frame: From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
Overall Response Rate (ORR): Percentage of Participants With Overall Response
For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of \>=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause, whichever occurred first (maximum duration: up to 2 years)
Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment
ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
Time frame: From Baseline up to 2 years
Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment
ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
Time frame: From Baseline up to 2 years
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab
Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.
Time frame: At start of infusion (SOI), before actual end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810
Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.
Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab
AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.
Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810
AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.
Time frame: At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose on Day 1 of Cycle 1
Best Percent-change From Baseline in Tumor Burden
Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
Time frame: Up to 2 years
Duration of Response (DOR)
DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline \>=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.
Time frame: From the date of first response until disease progression or death, whichever occurred first (maximum duration: up to 2 years)
Progression-free Survival (PFS)
For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.
Time frame: From the date of the first study treatment administration to the date of first documented disease progression or death of any cause, whichever occurred first (maximum duration: up to 2 years)
Percentage of Participants With Disease Control (DC) >=6 Months
Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.
Time frame: From the date of first response to the date of first documented disease progression or death (due to any cause) (maximum duration: up to 2 years)
Study was conducted at 16 active sites in 5 countries. A total of 44 participants were enrolled between 04 January 2018 and 18 January 2019 and received isatuximab in combination with REGN2810.
| Milestone | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Started | 24 | 20 |
| Completed | 0 | 1 |
| Not completed | 24 | 19 |
| Withdrew: Adverse event | 4 | 4 |
| Withdrew: Progressive disease | 15 | 13 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Other | 4 | 2 |
DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to \[\>=\] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G\>=2 uveitis, G3 non-hematological AE lasting greater than (\>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 \>14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 |
An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Any TEAEs | 24 | 20 |
| Any TESAEs | 11 | 14 |
Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Anemia: Grade 1 | 10 | 9 |
| Anemia: Grade 2 | 9 | 2 |
| Anemia: Grade 3 | 4 | 3 |
| WBC decreased: Grade 1 | 8 | 2 |
| WBC decreased: Grade 2 | 5 | 0 |
| Platelet count decreased: Grade 1 | 5 | 1 |
| Platelet count decreased: Grade 2 | 2 | 0 |
| Platelet count decreased: Grade 3 | 1 | 0 |
| Lymphocyte count decreased: Grade 1 | 4 | 7 |
| Lymphocyte count decreased: Grade 2 | 8 | 4 |
| Lymphocyte count decreased: Grade 3 | 5 | 2 |
| Lymphocyte count decreased: Grade 4 | 1 | 0 |
| Neutrophil count decreased: Grade 1 | 3 | 2 |
| Neutrophil count decreased: Grade 2 | 2 | 0 |
Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Hyponatremia: Grade 1 | 8 | 8 |
| Hypokalemia: Grade 1 | 3 | 2 |
| Hyperkalemia: Grade 1 | 3 | 2 |
| Hypocalcemia: Grade 1 | 6 | 3 |
| Hypocalcemia: Grade 2 | 1 | 0 |
| Hypercalcemia: Grade 1 | 1 | 1 |
| Hypercalcemia: Grade 2 | 0 | 1 |
| Hypoalbuminemia: Grade 1 | 6 | 2 |
| Hypoalbuminemia: Grade 2 | 1 | 3 |
| Hypoalbuminemia: Grade 3 | 0 | 1 |
| Hyperglycemia: Grade 1 | 11 | 3 |
| Hyperglycemia: Grade 2 | 5 | 5 |
| Hyperglycemia: Grade 3 | 1 | 0 |
| Hypoglycemia: Grade 1 | 0 | 1 |
| Hypoglycemia: Grade 2 | 0 | 1 |
Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: \>=60 - less than (\<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m\^2), \>=30 - \<60 mL/min/1.73m\^2, \>=15 - \<30 mL/min/1.73m\^2 and \<15 mL/min/1.73m\^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| CrCl: >=60 - <90 mL/min/1.73m^2 | 6 | 13 |
| CrCl: >=30 - <60 mL/min/1.73m^2 | 11 | 2 |
| Creatinine increased: Grade 1 | 18 | 15 |
| Hyperuricemia: Grade 3 | 2 | 3 |
| Hyperuricemia: Grade 4 | 1 | 0 |
Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
| Participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| AST increased: Grade 1 | 6 | 2 |
| AST increased: Grade 2 | 1 | 0 |
| ALT increased: Grade 1 | 2 | 0 |
| ALP increased: Grade 1 | 3 | 9 |
| ALP increased: Grade 2 | 4 | 0 |
| ALP increased: Grade 3 | 6 | 0 |
| BB increased: Grade 1 | 2 | 1 |
For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of \>=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
| percentage of participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Overall Response Rate (ORR): Percentage of Participants With Overall Response | 4.2 (0.2 to 18.3) | 0 (0.0 to 13.9) |
ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
| Participants | mCRPC + NSCLC : Isatuximab + REGN2810 |
|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment | 0 |
ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
| Participants | mCRPC + NSCLC : Isatuximab + REGN2810 |
|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment | 1 |
Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.
| micrograms per milliliter | mCRPC: Isatuximab | NSCLC: Isatuximab |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab | 291 ± 67.9 | 280 ± 54.5 |
Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.
| milligrams per liter | mCRPC: REGN2810 | NSCLC: REGN2810 |
|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810 | 102 ± 26.1 | 116 ± 21.4 |
AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.
| micrograms*hour per milliliter | mCRPC: Isatuximab | NSCLC: Isatuximab |
|---|---|---|
| Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab | 28400 ± 6610 | 24500 ± 5510 |
AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.
| milligrams*day per liter | mCRPC: REGN2810 | NSCLC: REGN2810 |
|---|---|---|
| Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810 | 903 ± 257 | 1020 ± 229 |
Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
| percent change | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Best Percent-change From Baseline in Tumor Burden | 12.9 ± 47.6 | 0.7 ± 10.1 |
DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline \>=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.
| months | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Duration of Response (DOR) | 4.17 | — |
For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.
| months | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Progression-free Survival (PFS) | 2.30 (1.906 to 4.271) | 4.01 (1.938 to 4.074) |
Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to \<10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.
| percentage of participants | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Percentage of Participants With Disease Control (DC) >=6 Months | 20.8 (8.6 to 38.9) | — |
Collected over From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mCRPC: Isatuximab + REGN2810 | 2/24 (8.3%) | 11/24 (45.8%) | 24/24 (100%) |
| NSCLC: Isatuximab + REGN2810 | 2/20 (10%) | 14/20 (70%) | 19/20 (95%) |
| Event | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| PneumoniaInfections and infestations | 0/24 | 2/20 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/24 | 2/20 |
| Infusion Related ReactionInjury, poisoning and procedural complications | 2/24 | 1/20 |
| Immune-Mediated EnterocolitisGastrointestinal disorders | 0/24 | 1/20 |
| Intestinal ObstructionGastrointestinal disorders | 0/24 | 1/20 |
| Malignant DysphagiaGastrointestinal disorders | 0/24 | 1/20 |
| Disease ProgressionGeneral disorders | 0/24 | 1/20 |
| Post Procedural HaematomaInjury, poisoning and procedural complications | 0/24 | 1/20 |
| Cancer PainNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 1/20 |
| Metastases To PeritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/24 | 1/20 |
| Event | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 |
|---|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 10/24 | 8/20 |
| Decreased AppetiteMetabolism and nutrition disorders | 9/24 | 1/20 |
| FatigueGeneral disorders | 8/24 | 3/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/24 | 6/20 |
| Back PainMusculoskeletal and connective tissue disorders | 7/24 | 1/20 |
| AstheniaGeneral disorders | 6/24 | 4/20 |
| PyrexiaGeneral disorders | 6/24 | 4/20 |
| DiarrhoeaGastrointestinal disorders | 5/24 | 2/20 |
| Oedema PeripheralGeneral disorders | 5/24 | 0/20 |
| NauseaGastrointestinal disorders | 4/24 | 3/20 |
Analysis was performed on all-treated population which included all participants who signed the study informed consent (IC) and received at least 1 dose (even incomplete) of the study treatments, either isatuximab or REGN2810.
| Age, Continuous(years) | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 | Total Title |
|---|---|---|---|
| Mean | 70.7 ± 6.5 | 65.4 ± 5.8 | 68.3 ± 6.7 |
| Sex: Female, Male(Participants) | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 | Total Title |
|---|---|---|---|
| Female | 0 | 6 | 6 |
| Male | 24 | 14 | 38 |
| Race (NIH/OMB)(Participants) | mCRPC: Isatuximab + REGN2810 | NSCLC: Isatuximab + REGN2810 | Total Title |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 5 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 18 | 10 | 28 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 4 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jan 2018 to primary completion in Mar 2021, 38 months.
Results were first posted in May 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab